Last reviewed · How we verify
NCT06265077
Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients
Phase 1, PHASE2 trial testing Placebo in Breast Cancer in 58 participants. Completed in 17 October 2024.
17 October 2024
Quick facts
| Lead sponsor | Noha Mansour |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 58 |
| Start date | 1 February 2024 |
| Primary completion | 17 October 2024 |
| Estimated completion | 17 October 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Placebo
- famotidine and loratadine — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Filgrastim Adverse Reaction — all drugs for Filgrastim Adverse Reaction →
Sponsor
Noha Mansour — full company profile →
Who can join
18 and older, any sex, with Breast Cancer or Filgrastim Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
No randomized controlled trial evaluated the safety and efficacy of double blockade on G-CSF induced bone pain. Therefore, this study aims to evaluate the efficacy and safety of double blockade on the incidence and severity of G-CSF induced bone pain.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications.
Li K, Guo B, Gu J, Ta N, et al · · 2025 · cited 8× · PMID 39759851 · DOI 10.1016/j.mtbio.2024.101375
Verify or expand the search:
- PubMed search for NCT06265077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Noha Mansour trials
Trials by the same sponsor.
- NCT05778838 — Midodrine Effect on the Mortality Rates in Septic Shock Patients · Phase 2 · completed
- NCT05447520 — Montelukast Use in Rheumatoid Arthritis · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06265077 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Noha Mansour
- Last refreshed: 13 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06265077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing